AlexisAnneThompsonMDMPH

Pediatric Hematology & Oncology • Philadelphia, PA

Pediatric Anemia and Red Blood Cell Hematology

Chief, Division of Hematology, Children's Hospital of Philadelphia, Professor in Pediatrics, University of Pennsylvania Perelman School of Medicine

Join to view full profile

Dr. Thompson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thompson's full profile

Already have an account?

Office
3401 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-590-2363

Summary

Dr. Alexis Thompson is a pediatric hematologist/oncologist in Philadelphia, PA and is affiliated with the Children's Hospital of Philadelphia. She received her medical degree from Tulane University School of Medicine and has been in practice 34 years. She specializes in pediatric anemia and red blood cell hematology and is experienced in thalassemias, sickle-cell anemia, anemia, and sickle cell anemia. She has more than 150 publications and over 500 citings.

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1988 - 1990
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1987 - 1990
Children's Hospital Los AngelesResidency, Pediatrics, 1985 - 1986
Childrens Hospital Los AngelesInternship, Transitional Year, 1983 - 1984
Tulane University School of MedicineClass of 1983

Certifications & Licensure

CA State Medical License 1984 - Present
PA State Medical License 1987 - 2024
IL State Medical License 2001 - 2023
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia Start of enrollment: 1999 Jan 01
Completed
Phase 2
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment Start of enrollment: 2006 Feb 01
Completed
Phase 2
Assessment of Pain in People With Thalassemia Start of enrollment: 2009 Mar 01
Completed
Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions Start of enrollment: 2009 Jul 01
Completed
Exercise Capacity in Pediatric Sickle Cell Anemia Start of enrollment: 2009 Jun 01
Completed
Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia Start of enrollment: 2012 Jan 01
Unknown status
Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia Start of enrollment: 2012 Sep 01
Completed
Phase 1, Phase 2
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) Start of enrollment: 2013 Apr 01
Terminated
Phase 3
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP Start of enrollment: 2013 Aug 01
Completed
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) Start of enrollment: 2014 Jul 08
Completed
Phase 2
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children Start of enrollment: 2019 May 02
Active, not recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1427 citations
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J. Manco-Johnson, Thomas C. Abshire, Amy D. Shapiro, Brenda Riske, Michele R. Hacker
The New England Journal of Medicine. 2007-08-09
126 citations
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
Julie Kanter, Mark C Walters, Lakshmanan Krishnamurti, Markus Y Mapara, Janet L Kwiatkowski
The New England Journal of Medicine. 2022-02-17
4098 citations
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
Andrew Tonkin, P. Alyward, David Colquhoun, Paul Glasziou, P. Harris
The New England Journal of Medicine. 1998-11-05

Abstracts/Posters

Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent _-Thalassemia in the Northstar (HGB-204) Study
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease
Alexis A Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency
Alexis A Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Probably Pathogenic KMT2D Variants Presenting with Cytopenias and Primary Immune Deficiency
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent _-Thalassemia and Either a _0 or IVS-I-110...
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent _-Thalassemia in the Northstar (HGB-204) Study
Alexis A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent _-Thalassemia and Non-_0/_0 Genotypes
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Friday Scientific Workshop on Novel Curative Options: Gene-Editing and Gene Therapy for Hemoglobinopathies with a Focus on Sickle Cell Disease
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medal
60th American Society of Hematology Annual Meeting - 12/4/2018
Business Meeting
60th American Society of Hematology Annual Meeting - 12/4/2018
Completing the Genome Editing Arc in Hematology
60th American Society of Hematology Annual Meeting - 12/4/2018
ASH Research Collaborative SCD Clinical Trials Network Q&A
60th American Society of Hematology Annual Meeting - 12/3/2018
Blood Stem Cells: A Simple Concept, but a Complex Reality
60th American Society of Hematology Annual Meeting - 12/3/2018
Bone Marrow Failure: Fanconi Anemia and Aplastic Anemia
60th American Society of Hematology Annual Meeting - 12/3/2018
Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outsta...
60th American Society of Hematology Annual Meeting - 12/2/2018
Constitutional Syndromes With Malignant Potential
60th American Society of Hematology Annual Meeting - 12/2/2018
Plenary Scientific Session
60th American Society of Hematology Annual Meeting - 12/2/2018
Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar Hgb-204 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Bluebird Bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 5th, 2024
Children's Hospital of Philadelphia Leader in Sickle Cell Disease Elected to National Academy of MedicineOctober 21st, 2024
Philadelphia Health Providers and Patients Seek a New Treatment Roadmap for Sickle Cell Disease After Drug RecallOctober 10th, 2024
Join now to see all